ReviewHepatology international2016
Genetic and epigenetic mechanisms of NASH.
Review in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Development and Validation of Machine Learning-Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.Therapeutic advances in endocrinology and metabolism · 2024Review
- Gut microbiota in MAFLD: therapeutic and diagnostic implications.Therapeutic advances in endocrinology and metabolism · 2024Review
- Exportin 4 DNA promoter methylation in liver fibrosis.PloS one · 2024Article
- Two years on, a perspective on MAFLD.eGastroenterology · 2023Review
- The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression.The Journal of experimental medicine · 2023Article
- Article
- Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nature reviews. Gastroenterology & hepatology · 2022Review
- Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.Journal of clinical laboratory analysis · 2022Article
- Combination Therapies for Nonalcoholic Fatty Liver Disease.Journal of personalized medicine · 2022Review
- Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update.Journal of clinical and translational hepatology · 2022Review
- Oral-Gut Microbiome Analysis in Patients With Metabolic-Associated Fatty Liver Disease Having Different Tongue Image Feature.Frontiers in cellular and infection microbiology · 2022Article
- Genetic variation in TBC1 domain family member 1 gene associates with the risk of lean NAFLDFrontiers in genetics · 2022Article
- Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.Biomedicines · 2021Review
- Genetic Polymorphism of Vitamin D Family GenesFrontiers in genetics · 2021Article
- Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.Frontiers in endocrinology · 2021Review
- History of Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2020Review
- Association of Genetic and Environmental Factors with Non-Alcoholic Fatty Liver Disease in a Chinese Han Population.International journal of environmental research and public health · 2020Article
- Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.Cellular and molecular life sciences : CMLS · 2020Review
- Macrophages in metabolic associated fatty liver disease.World journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Along with the obesity epidemic, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased exponentially. The histological disease spectrum of NAFLD ranges from bland fatty liver (hepatic steatosis), to the concomitant presence of inflammation and ballooning which defines nonalcoholic steatohepatitis (NASH). The latter can progress in a subset to fibrosis, leading ultimately to cirrhosis and hepatocellular carcinoma. The past decade has seen tremendous advances in our understanding of the genetic and epigenetic bases of NAFLD, mainly through the application of high end technology platforms including genome-wide association studies (GWAS). These have helped to define common gene variants (minor allele frequency >5 %) that contribute to the NAFLD phenotype. Looking to the future, these discoveries are expected to lead to improved diagnostics, the personalization of medicine, and a better understanding of the pathophysiological underpinnings that drive the transition from NAFLD to steatohepatitis and fibrosis, leading to the identification of novel therapeutic targets. In this review, we summarize data on the current state of knowledge with regard to the genetic and epigenetic mechanisms for the development of NASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.